8-K
ALLURION TECHNOLOGIES, INC. (ALUR)
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): March 11, 2024 |
|---|
Allurion Technologies, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-41767 | 92-2182207 |
|---|---|---|
| (State or Other Jurisdiction<br>of Incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |
| 11 Huron Drive | ||
| Natick, Massachusetts | 01760 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| Registrant’s Telephone Number, Including Area Code: (508) 647-4000 | ||
| --- | ||
| Not Applicable | ||
| --- |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br>Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common stock, par value $0.0001 per share | ALUR | The New York Stock Exchange |
| Warrants to purchase 1.420455 shares of common stock, each at an exercise price of $8.10 per share of common stock | ALUR WS | The New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 11, 2024, the Board of Directors (the "Board") of Allurion Technologies, Inc. ("Allurion" or the "Company") appointed Milena Alberti-Perez to the Board as a Class III director to fill the vacancy on the Board, effective immediately. Ms. Alberti-Perez also was appointed to the Audit Committee of the Board and will serve as the Chair of such committee. The election of Ms. Alberti-Perez puts the Company in compliance with the New York Stock Exchange ("NYSE") listing requirement 303A.07, which requires that the Company’s Audit Committee be comprised of at least three directors, all of whom are independent. The Board has affirmatively determined that Ms. Alberti-Perez is “independent” under the listing standards of the NYSE and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), including applicable rules thereof related to service on audit committees.
Ms. Alberti-Perez’s compensation for her services as a non-employee director will be consistent with the Company’s compensation practices for non-employee directors described in the Company’s Registration Statement on Form S-4/A filed with the SEC on July 6, 2023 under the caption “Allurion Non-Employee Director Compensation Policy.”
There is no arrangement or understanding between Ms. Alberti-Perez and any other person pursuant to which she was to be selected as a director of the Company, and she is a not a party to, and has no direct or indirect interest in, any transactions or proposed transactions to which the Company is or will be a participant.
A copy of the press release dated March 11, 2024, announcing such appointments is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit | Description |
|---|---|
| 99.1 | Press Release issued by the registrant on March 11, 2024, furnished herewith. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: | March 14, 2024 | By: | /s/ Brendan Gibbons |
|---|---|---|---|
| Chief Legal Officer |
EX-99.1
EX-99.1

Milena Alberti-Perez Joins Allurion Board of Directors as Audit Committee Chair
NATICK, MA – March 12, 2024 – Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the appointment of its newest board member and Audit Committee Chair, Milena Alberti-Perez, effective as of March 11, 2024.
"Milena joins the Allurion board during an exciting time in the company’s history and is a proven and dynamic leader, with deep experience as an operator and board member," said Dr. Shantanu Gaur, Allurion Founder and CEO. "Her perspective and guidance will be invaluable as Allurion furthers its mission to treat the one billion people around the world with obesity.”
Ms. Alberti-Perez previously served as Chief Financial Officer at Getty Images (NYSE: GETY) and CFO at Penguin Random House where she oversaw a global business generating over $3 billion in annual sales. She currently serves as Chair of the Audit Committee at Digimarc Corporation (Nasdaq: DMRC) and Chair of the Finance Committee and member of the Audit Committee at Pitney Bowes (NASDAQ: PBI)
“I am thrilled to join Allurion at a pivotal stage of its journey as a public company,” said Ms. Alberti-Perez. “I am looking forward to working with my fellow board members and the company’s management team as Allurion embarks on setting a new standard for a best-in-class weight loss experience.”
Ms. Alberti-Perez holds a B.A. from the University of Pennsylvania and an M.B.A. from Harvard Business School.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan, whether it is gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.
Global Media Cedric Damour PR Manager +33 7 84 21 02 20 cdamour@allurion.com
Investor Contact Mike Cavanaugh, Investor Relations ICR Westwicke (617) 877-9641 mike.cavanaugh@westwicke.com